（NewsNation）——GLP-1类药物继续被视为阻塞性睡眠呼吸暂停（OSA）的治疗选择之一，但研究人员表示，CPAP仍是该病症的首选治疗方案。
(NewsNation) — GLP-1 medications continue to be discussed as a treatment option for obstructive sleep apnea, but researchers say CPAP remains the preferred treatment for the condition.
这项发表在《JAMA耳鼻喉头颈外科》上的综述发现，减肥药物能持续降低呼吸暂停低通气指数（AHI）评分，这意味着患者在睡眠期间的呼吸中断次数减少。
The review, published in JAMA Otolaryngology–Head & Neck Surgery, found that the weight loss drugs consistently reduce apnea-hypopnea index (AHI) scores, meaning patients experience fewer breathing interruptions during sleep.
研究人员表示，服用替尔泊肽（Tirzepatide，商品名Zepbound、Mounjaro）的人群效果尤为显著。这些药物似乎还能减少舌部脂肪。
Researchers said the effects were particularly strong in people taking tirzepatide (Zepbound, Mounjaro). The medications also appear to reduce tongue fat.
拉奇尔·P·帕特尔博士（Dr. Ruchir P. Patel）向Healthline表示：“然而，替尔泊肽仅针对OSA的一个风险因素——肥胖。OSA的发生还涉及其他因素，包括与脂肪沉积无关的结构性解剖问题，这些问题无法通过减肥来解决。”分析还表明，GLP-1类药物可能通过改变呼吸控制系统的敏感性来帮助稳定呼吸。这些药物持续减少了呼吸暂停和低通气发作，每小时减少6至22次。CPAP机器可将同样的症状减少约每小时31次。
“Tirzepatide, however, addresses a single risk factor in the setting of OSA — obesity,” Dr. Ruchir P. Patel told Healthline. “There are other factors involved in the development of OSA, including structural anatomy unrelated to fat deposits that cannot be addressed by weight loss.” The analysis also suggests GLP-1s could help stabilize breathing by altering the sensitivity of respiratory control systems. The drugs consistently reduced apnea and hypopnea episodes, ranging from six to 22 fewer events per hour. CPAP machines reduce those same symptoms by about 31 events per hour.
帕特尔补充道：“多年来，通过减重手术文献，我们已知显著的体重减轻并不总能解决OSA问题。因此，虽然症状可能会改善，但患者仍可能面临风险。”60%至70%的OSA患者存在肥胖问题，这是主要的可改变风险因素。
“[W]e have known for many years through the bariatric surgery literature that significant weight loss does not always resolve OSA,” Patel added. “So, while symptoms may improve, the patient could still be at risk.” Obesity is present in 60 percent to 70 percent of patients with OSA and represents the primary modifiable risk factor.